Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: Evidence of resistance to apoptosis induction

Stem Cells

Volumn 24, Issue 12, 2006, Pages 2753-2765

  Mueller, Lutz P ^a   Luetzkendorf, Jana ^a   Mueller, Thomas ^a   Reichelt, Katrin ^a   Simon, Heike ^a   Schmoll, Hans Joachim ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Apoptosis; Chemotherapy; MSCs; Resistance

Indexed keywords

ASPARAGINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; HYDROXYUREA; IDARUBICIN; IFOSFAMIDE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; PROTEIN P53; TENIPOSIDE; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; GENOTOXICITY; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MALE; MESENCHYMAL STEM CELL; PHENOTYPE; PROTEIN EXPRESSION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; CASPASE 9; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SEPARATION; DRUG RESISTANCE; ENZYME ACTIVATION; FEMALE; FIBROBLASTS; HUMANS; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; MUTAGENS; PHENOTYPE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846006502     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2006-0108     Document Type: Article

References (43)

1. Friedenstein AJ, Petrakova KV, Kurolesova AI et al. Heterotopic transplants of bone marrow: Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968;6:230-247.
2. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
3. Horwitz EM, Le Blanc K, Dominici M et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005;7:393-395.
4. Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309-313.
5. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441.
6. Studeny M, Marini FC, Dembinski JL et al. Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593-1603.
7. Koc ON, Peters C, Aubourg P et al. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp Hematol 1999;27: 1675-1681.
8. Gussoni E, Bennett RR, Muskiewicz KR et al. Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation. J Clin Invest 2002;110:807-814.
9. Li J, Law HK, Lau YL et al. Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. Br J Haematol 2004;127:326-334.
10. Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science 1998;281:1312-1316.
11. Haupt S, Berger M, Goldberg Z et al. Apoptosis - The p53 network. J Cell Sci 2003;116:4077-4085.
12. Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005;331:851-858.
13. Reyes M, Lund T, Lenvik T et al. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001;98:2615-2625.
14. Casper J, Schmoll HJ, Schnaidt U et al. Cell lines of human germinal cancer. Int J Androl 1987;10:105-113.
15. Baxter MA, Wynn RF, Jowitt SN et al. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. STEM CELLS 2004;22:675-682.
16. Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-1112.
17. Kellner U, Sehested M, Jensen PB et al. Culprit and victim - DNA topoisomerase II. Lancet Oncol 2002;3:235-243.
18. Siddik ZH. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-7279.
19. Hanada K, Nishijima K, Ogata H et al. Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: Possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum. Jpn J Clin Oncol 2001;31:179-184.
20. Nagai N, Ogata H, Wada Y et al. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: Analysis with the NONMEM program. J Clin Pharmacol 1998;38:1025-1034.
21. Braybrooke JP, Levitt NC, Joel S et al. Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression. Clin Cancer Res 2003;9:4682-4688.
22. Spyridonidis A, Kuttler T, Wasch R et al. Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin. Stem Cells Dev 2005;14:213-222.
23. Simmons PJ, Przepiorka D, Thomas ED et al. Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature 1987;328:429-432.
24. Banfi A, Bianchi G, Galotto M et al. Bone marrow stromal damage after chemo/radiotherapy: Occurrence, consequences and possibilities of treatment. Leuk Lymphoma 2001;42:863-870.
25. Carlo-Stella C, Tabilio A, Regazzi E et al. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors. Bone Marrow Transplant 1997;20:465-471.
26. Devine SM, Hoffman R. Role of mesenchymal stem cells in hematopoietic stem cell transplantation. Curr Opin Hematol 2000;7:358-363.
27. Galotto M, Berisso G, Delfino L et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol 1999;27:1460-1466.
28. Domenech J, Roingeard F, Herault O et al. Changes in the functional capacity of marrow stromal cells after autologous bone marrow transplantation. Leuk Lymphoma 1998;29:533-546.
29. Huss R, Moosmann S. The co-expression of CD117 (c-kit) and osteocalcin in activated bone marrow stem cells in different diseases. Br J Haematol 2002;118:305-312.
30. Murphy JM, Dixon K, Beck S et al. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum 2002;46:704-713.
31. Papadaki HA, Kritikos HD, Gemetzi C et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: Evidence for a tumor necrosis factor alpha-mediated effect. Blood 2002;99:1610-1619.
32. Rodriguez JP, Garat S, Gajardo H et al. Abnormal osteogenesis in osteoporotic patients is reflected by altered mesenchymal stem cells dynamics. J Cell Biochem 1999;75:414-423.
33. Nishida S, Endo N, Yamagiwa H et al. Number of osteoprogenitor cells in human bone marrow markedly decreases after skeletal maturation. J Bone Miner Metab 1999;17:171-177.
34. Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002;99:8932-8937.
35. Kuwahara D, Tsutsumi K, Kobayashi T et al. Caspase-9 regulates cisplatin-induced apoptosis in human head and neck squamous cell carcinoma cells. Cancer Lett 2000;148:65-71.
36. Mueller T, Voigt W, Simon H et al. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res 2003;63:513-521.
37. Mueller T, Mueller LP, Luetzkendorf J et al. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. Tumor Biol 2006;27:71-83.
38. Shiozaki EN, Chai J, Rigotti DJ et al. Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell 2003;11:519-527.
39. Kottke TJ, Blajeski AL, Meng XW et al. Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells. J Biol Chem 2002;277:804-815.
40. Aladjem MI, Spike BT, Rodewald LW et al. ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr Biol 1998;8:145-155.
41. Hong Y, Stambrook PJ. Restoration of an absent G1 arrest and protection from apoptosis in embryonic stem cells after ionizing radiation. Proc Natl Acad Sci U S A 2004;101:14443-14448.
42. de Waard H, de Wit J, Gorgels TG et al. Cell type-specific hypersensitivity to oxidative damage in CSB and XPA mice. DNA Repair (Amst) 2003;2:13-25.
43. Van Sloun PP, Jansen JG, Weeda G et al. The role of nucleotide excision repair in protecting embryonic stem cells from genotoxic effects of UV-induced DNA damage. Nucleic Acids Res 1999;27:3276-3282.